Follow the RemeGen Co., Ltd. - H Shares share price and the full directors' dealings record of the company, a publicly traded company based in Hong Kong. Shares are listed on HK HK, under the authority of HKEX. The latest transaction was disclosed on 10 July 2026 (Sale). Among the most active insiders: Lin Jian. All data is openly available.
39
Insider Decl.
0
Thresholds
·
26 ops.
Buy Volume
€321,435
4 ops.
Sell Volume
11Σ signal
Buys ·€321,435 Sells
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 2,925 of 26,282 companies
72.7
score / 100
Value
63
Quality
82
FCF yld-2.2%
Earn yld10%
EV/EBITDA8.2x
ROE45%
Gross mgn87%
Net mgn22%
Debt/EBITDA2.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
RemeGen Co., Ltd. is a Chinese biopharmaceutical company focused on the research and development of innovative treatments for cancer and other autoimmune diseases. It is listed on the H-share market.